a b s t r a c t HIV and M. tuberculosis are two intersecting epidemics making the search for new dual action drugs against both pathogens extremely important. Here, we report on the synthesis and suppressive activities of five dual-targeted HIV/TB compounds. These compounds are heterodimers of AZT, as anti-HIV molecules, and 5-substituted uracil derivatives, as anti-TB molecules. We found that these compounds inhibit the growth of M. tuberculosis and suppress the replication of HIV in human cell cultures and human lymphoid tissues ex vivo. We identified one particular heterodimer that inhibited both HIV and the drugresistant TB strain MS-115 most potently. This compound demonstrated low toxicity and had no cytostatic effect on cells in culture, constituting an ideal candidate for future development and further in vivo testing.
Introduction
Infection by HIV and M. tuberculosis are among the main causes of death from infectious diseases worldwide. According to 2015 WHO estimates, 2.1 million people became newly infected with HIV and 1.1 million people died from AIDS-related illnesses. In 2015, among the causes of death from infectious diseases, tuberculosis (TB) ranked above HIV/AIDS, with an estimated 10.4 million new cases and 1.8 million deaths (Organization WH, 2016) .
The HIV and TB epidemics fully intersect. On one hand, the risk of death in TB/HIV-coinfected individuals is twice that in HIVinfected individuals without TB, even when CD4 cell counts and antiretroviral therapy are taken into account (Suchindran et al., 2009) . On the other hand, HIV infection is the strongest known risk factor for progressing to TB disease for individuals with latent TB infection. Also, people living with HIV are 17e22 times more likely to develop TB than people without HIV. Apparently, M. tuberculosis and HIV act synergistically, resulting in a decline of immunological functions and death if untreated (Pawlowski et al., 2012) .
The synergy between TB and HIV makes the search for new combined dual-action drugs extremely important. In general, combining two active compounds into one molecule has a long history (Puech et al., 1990; Velazquez et al., 1995 Velazquez et al., , 1999 Pontikis et al., 2000; Laduree et al., 2003) . In particular, we reported earlier on the synthesis of hybrid antivirals by linking two nucleoside reverse transcriptase inhibitors (NRTI) of HIV (Vanpouille et al., 2014) .
Here, we describe five new anti-TB/anti-HIV compounds that are based on heterodimerization of our recently designed anti-TB 5-arylaminouracil derivative (Matyugina et al., 2015) as well as of 2 0 -deoxyuridine analogues (Shmalenyuk et al., 2013) with the anti-HIV NRTI 3 0 -azido-3 0 -deoxythymidine (AZT). These compounds inhibit the growth of M. tuberculosis and suppress the replication of HIV in human cell cultures and human lymphoid tissues ex vivo. Four of the synthesized compounds proved to be of low cytotoxity in these systems.
Materials and methods

Chemical synthesis
Chemical synthesis and spectroscopic characterizations are described in detail in the supplementary data file. Briefly, in this work, five new hybrid molecules were synthesized; three of them (1e3) are the conjugates of AZT and 5-(4-decyl-1,2,3-triazol-1-ylmethyl)-2 0 -deoxyuridine (dU R ) (Scheme 1) and the other two (4 and 5) are conjugates of AZT and modified 5 0 -norcarbocyclic analogues of 2 0 ,3 0 -dideoxy-2 0 ,3 0 -didehydrouridine (Scheme 2). A solution of dU R and 1,1 0 -carbonyldiimidazole in DMF was heated for 18 h at 37 C, and then AZT was added to have products 1e3
(Scheme 1). The reaction mixture was then evaporated and chromatographed on silica gel with a gradient concentration of ethanol in chloroform. For the synthesis of heterodimers 4 and 5, the previously described method of selective N-3 alkylation was used (Velazquez et al., 1995) . The reaction of AZT and dibromopropane in the presence of potassium carbonate gave intermediate 6 (15% yield), to which the second key component, 7 or 8, was further added Scheme 1. Synthesis of heterodimers of AZT and 5-(4-decyl-1,2,3-triazol-1-yl-methyl)-2 0 -deoxyuridine.
Scheme 2. Synthesis of heterodimers of AZT and the 5 0 -norcarbocyclic analogues of 2 0 ,3 0 -dideoxy-2 0 ,3 0 -didehydrouridine.
(Scheme 2). The yields of the heterodimers 4 and 5 on the second stage were 60% and 65%, respectively.
Structures and purities of the synthesized compounds 1e5 were confirmed from 1 H and 13 C NMR spectroscopy, high-resolution mass spectroscopy, and TLC.
Stability of compounds synthesized
Chemical stability at pH 2.2, 7.4, and 9.0, as well as stability in human blood serum, were evaluated according to the standard procedures (Khandazhinskaya et al., 2002 (Khandazhinskaya et al., , 2009 ). We performed HPLC-HRMS analysis of the samples using an Agilent 1260 chromatograph equipped with an Agilent Poroshell-120 column (3.0 Â 50 mm; 2.7 mm) and a Phenomenex SecurityGuard Ultra C-18 precolumn and used a Bruker Daltonics micrOTOF-Q II massspectrometer for detection. The column was eluted in a gradient of acetonitrile (A) in water (B). Gradient parameters: 100% B for 2 min; 10% / 20% A for 2 min, 20% / 30% A for 2 min, 30% / 40% A for 2 min, 40% / 50% A for 2 min, 50% / 60% A for 2 min, 60% / 70% A for 2 min, 70% / 80% A for 2 min, 80% / 90% A for 2 min, 90% / 100% A for 2 min; 100% A for 5 min, and 100% / 0% A for 5 min. Flow rate was set at 0.130 mL/min.
Anti-HIV-1 activity
HIV-1 inhibition by compounds (1e5) was assessed in MT-4 cell cultures and in human tissues ex vivo.
MT-4 cell cultures
Human T lymphocytes MT-4 (obtained from American Type Culture Collection) were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum. We performed HIV-1 infection of MT-4 by incubating 100 mL of MT-4 at 10 7 cells/mL with 100 mL of a prototypical X4 variant of HIV-1 (X4 LAI.04 ) (Rush University Virology Quality Assurance Laboratory, Chicago, IL) containing 7 ng of p24 gag in a vial for 1 h 30 min at 37 C. After incubation, infected cell suspensions were washed with phosphate-buffered saline (PBS) and resuspended in 1 mL of medium. We first transferred 100 mL of infected MT-4 cells to a 12-well plate and then mixed them with 900 mL of medium containing the test compound at an appropriate dilution. MT-4 cells were incubated at 37 C and cultured for 3 days.
Human tissue culture ex vivo
Human tonsillar tissues were obtained from patients undergoing routine tonsillectomy at the Children's National Medical Center (Washington, DC) under an IRB-approved protocol. Tissues were dissected into 2-to 3-mm 3 blocks and placed onto collagen sponge gels in culture medium at the aireliquid interface as described earlier (Biancotto et al., 2009) . Human tonsillar tissues (27 blocks of tissue from each of n donors for each experimental condition) were pretreated with compounds (1e5) overnight and then infected with (HIV-1 X4 LAI.04 ). The tissue culture was kept for 12 days, and drugs were replenished after each medium change (every 3 days).
Evaluation of antiviral activity of compounds (1e5)
We measured p24gag using a bead-based Luminex assay as described earlier (Biancotto et al., 2009) . We then evaluated the antiviral activity of each compound by measuring inhibition of human HIV-1 replication in MT-4 cell cultures and in human lymphoid tissues. For each compound, HIV-1 inhibition at each single concentration was defined by the following formula: inhibition ¼ (1-R compounds /R Ctl )Â100, where R compounds and R Ctl are the amounts of p24 accumulated in the medium in compoundtreated cultures and in untreated cultures, respectively. We calculated the EC 50 values (with 95% confidence interval (CI)) by fitting the data points to a sigmoidal doseeresponse curve, using Prism software, (version 6.0; GraphPad). The EC 50 (50% effective concentration) is defined as the compound concentration required for inhibition of viral replication by 50%.
Cell toxicity
Cell toxicity was assessed both in MT-4 cell cultures and in human lymphoid tissue.
Viability assay in MT-4 cell cultures
We performed viability assays (cytotoxicity and cytopathicity) in MT-4 cell cultures with the Nucleocounter automated cell counting system (ChemoMetec). We determined the numbers of total cells and of dead cells in control (untreated) cultures and in cultures treated with heterodimers (1e5) using a propidium iodideebased assay according to the manufacturer's protocol. We collected and analyzed data using Nucleoview software (version 1.0; ChemoMetec).
Viability assay in human lymphoid tissue
To assess the cytotoxicity of heterodimers in human tonsillar tissues, we isolated cells from the compound-treated and untreated tissue blocks and stained them for surface markers. Each cell suspension was divided into two fractions and used for two different stainings. The first fraction was stained with a combination of the following fluorescence-labeled monoclonal antibodies: antieCD3-QD655, antieCD4-QD605, antieCD8-QD800, antieCD45RA-FITC, and antieCCR7-PE-Cy7. The second fraction was stained with the following antibodies: antieCD3-QD655, antieCD4-QD605, antieCD8-QD800, antieCD25-APC, antieCD38-PE, antieCD95-PECy7, and antieHLA-DR-BV570 (Caltag Laboratories, CA; B&D Biosciences, CA). Data were acquired and analyzed on a NovoCyte flow cytometer (AceaBisociences, Inc). We quantified cell depletion using Trucount beads (Becton Dickinson) for volumetric control and normalized cell numbers by tissue-block weights.
Anti-TB activity
Two strains of M. tuberculosis, H37Rv and MS-115, were used for testing the anti-TB activity of the synthesized heterodimers. The former strain is sensitive to standard anti-TB drugs, while the latter was MDR-resistant (Matyugina et al., 2012 (Matyugina et al., , 2015 . The cultures were checked for the absence of contamination by nonspecific microflora. We evaluated the anti-mycobacterial effects of the compounds as bacterial growth in enriched Middlebrook 7H9 liquid medium, using the BACTEC MGIT960 automated system registration in the presence of different concentrations of compounds (Matyugina et al., 2012) . Each concentration of the test compounds, as well as the control samples, were tested in triplicate. The resistance of MS-115 was confirmed in the experiments in which the strain was cultured in media containing rifampicin (1 mg/mL) and isoniazid (0.1 mg/mL). We found that its growth was similar to that in the media without these compounds. Levofloxacin (1.5 mg/mL) was used as a positive control.
Results
Stability of compounds synthesized
All the tested compounds were stable to chemical hydrolysis at рН 2.2 (glycineþHCl) and at рН 7.4 (PBS). Compounds 4 and 5 were also stable at рН 9.0 (glycineþNaOH); T 1/2 for compounds 1e3 at the same conditions was about 14e15 h. antigen. Infected cell suspensions were then transferred to 12-well plates, mixed with 1 mL of medium containing the test compound at an appropriate dilution, further incubated at 37 C, and cultured for 3 days. Cells were treated with increasing concentrations of heterodimers 1e5. Each graph represents HIV-1 inhibition as log10 of each heterodimer (1 to 5). EC 50 were estimated from six independent experiments, each of them testing ten different concentrations. The anti-HIV activity was evaluated from the suppression of viral replication compared with untreated MT-4 cell cultures. Depending on the concentration and the compound, HIV-1 suppression was calculated from two to nine independent experiments. We estimated the EC 50 and 95% confidence interval by fitting the data to four-parameter logistic regression. B. Human lymphoid tissues. Blocks of human tonsillar tissue were treated with increasing concentrations of heterodimers 1e5 and then inoculated ex vivo with X4 LAI.04 . The medium was changed and the drugs were replenished every three days. We monitored HIV-1 replication by measuring p24 gag accumulated in culture media over 3-day periods. For each donor, each datum represents pooled viral release from 27 tissue blocks. EC 50 were estimated from independent experiments performed with tonsillar tissues from seven different donors testing a total of 11 different concentrations. The anti-HIV activity was evaluated from the suppression of viral replication compared with donor-matched HIV-infected tissues not treated with heterodimers. We estimated the 50% effective concentration (EC 50 ) and 95% confidence interval by fitting the data to four-parameter logistic regression.
Similar T 1/2 values for compounds 1e3 were obtained in human blood serum (see Fig. S1 Supplementary) . Serum activity was assessed with the standard compounds: T 1/2 for 3 0 ,5 0 -diacetyl thymidine (Ac 2 T) was 18 h; T 1/2 for thymidine 5 0 -monophosphate (TMP) was 20 min. For compounds 1 and 2, both AZT and dU R derivative were found as main products. For compound 3, the entire set of hydrolysis products was detected: 1, 2, AZT, and dU R . Compound 4 produced only slight debenzoylation at the carbocyclic fragment after 15 h in human blood serum (debenzoylated product retention time was 19.50 min); compound 5 was stable. Retention times were as follows: 1, 22.10 min; 2, 22.50 min; 3, 23.05 min; 4, 21.85 min; 5, 21.10 min; AZT, 13.75 min; and dU R , 20.80 min.
Heterodimers inhibited HIV-1 replication
The anti-HIV activities of all the heterodimers (1e5) were evaluated in MT-4 cell cultures and in ex vivo human lymphoid tissues. All the compounds inhibited X4 LAI.04 replication in MT-4 cell cultures (Fig. 1A) . HIV-1 inhibition was assessed at increasing concentrations of heterodimers. HIV-1 inhibition was dosedependent, with EC 50 for heterodimers 1e3 being around 2 logs lower than that for heterodimers 4e5 (Table 1) . Similarly, we found that all compounds inhibited X4 LAI.04 replication in tissues ex vivo in a dose-dependent manner (Fig. 1B) . As described earlier (reviewed in (Biancotto et al., 2009) ), the absolute levels of HIV replication, evaluated from measurements of p24gag accumulation in culture medium, were donor-dependent. Therefore for each donor, HIV-inhibition in the treated experimental conditions was expressed as a percent of that in the donormatched untreated condition. Although EC 50 s were different from those in MT-4 cell cultures (Table 1) , heterodimers 1e3 were more potent than heterodimers 4e5 as observed in MT-4 cultures. EC 50 in human tissues ranged from 0.14 to 1.32 mM for heterodimers 1e3 and from 1.29 to 20.14 mM for heterodimers 4e5, respectively (Table 1) .
Heterodimers inhibited Mycobacterium tuberculosis
We evaluated anti-mycobacterial activities of the synthesized compounds using two M. tuberculosis strains: H37Rv, a laboratory strain sensitive to the five first-line anti-TB drugs (isoniazid, rifampicin, streptomycin, ethambutol, and pyrazinamide), and MS-115, a clinical MDR-resistant strain.
We found that compounds 1e3 and 5 exhibit anti-mycobacterial activity in the in vitro system. The minimal concentrations at which the inhibition of bacterial growth was not less than 99% for both strains MIC99 were determined ( Table 2) .
The anti-M. tuberculosis activity was the highest for EC 50 (with 95% confidence interval (CI)) were calculated by fitting the data points to a sigmoidal doseeresponse curve, using Prism software, (version 6.0; GraphPad). The EC 50 (50% effective concentration) is defined as the compound concentration required for inhibition of viral replication by 50%. Heterodimer (5) 10 μM Heterodimer (5) 50 μM E heterodimers 2 and 3. Indeed, the MIC99 of heterodimers 2 and 3 against the sensitive laboratory strain of M. tuberculosis H37Rv were respectively 13.5 mM and 19.3 mM, while they were respectively 27 mM and 9.7 mM against the clinical MDR strain of M. tuberculosis, MS-115. The MIC99 value for the parental compound dU R was 23 mM against both strains.
Heterodimers were not toxic for isolated cells or for tissue cultures
First, we tested the potential cell toxicity of our newlysynthesized heterodimers in human tissue ex vivo, which remains the model of choice to evaluate the potency and cytotoxicity of newly synthesized compounds (Grivel & Margolis, 2009) (Fig. 2) . Here, we tested the toxicity of each compound at two concentrations, 10 and 50 mM, with each experimental condition performed with 27 tissue blocks from each donor. After 12 days of culture, we isolated cells and assessed the viability of various lymphocyte subsets using flow cytometry. We evaluated the depletion of B cells (CD3 À ) and of various sets of T cells (CD3
and CD45RA À CCR7 -(effector memory, T EM ), at different states of
We assessed the cytotoxicity of each heterodimer by comparing the numbers of cells of each of the above-listed subsets in treated tissue blocks with those in donor-matched untreated tissue blocks. To account for size differences between tissue blocks, data were normalized by the tissue weight (Fig. 2) .
On day 12 of culture, the numbers of lymphocytes in the CD3 À ,
, T naïve , T CM , T EM , and activated T cell subsets were not statistically different (P > 0.05) in untreated tissues compared with donor-matched tissues treated with heterodimers 1e5 at a concentration of 10 mM. In contrast, when heterodimers were used at a concentration of 50 mM, mild cell depletion was observed (10e20% cell loss in treated versus untreated conditions). No particular heterodimer was more cytotoxic than the others.
Next, heterodimers were used in the MT-4 cell culture, allowing the evaluation of both their cytotoxic and cytostatic effects. For each compound, the CC 50 (concentration that reduced the viability of MT-4 by 50%) and the IC 50 (concentration that inhibited MT-4 cell growth by 50%) were evaluated. As in tissues, no significant cytotoxicity was observed for any of the five newly developed heterodimers (the CC 50 s ranged from 74 to >300 mM) (Table 3) . Although heterodimers were not toxic, some of them slowed down cell growth, with IC 50 s ranging from 18 to 150 mM. Heterodimer 3 was the least toxic and the least cytostatic, with both CC 50 > 300 mM and IC 50 ¼ 472.1 mM, as showed in Fig. 3 .
Discussion
Since coinfection of patients with TB and HIV is frequent, efficient compounds that suppress infection by both pathogens are required. Although single-targeted drugs are available, it is important to develop single compounds that target two or several pathogens.
Here, we report on the designing of dual-targeted compounds, hybrid molecules (heterodimers), made of two compounds respectively active against HIV and TB. Such a strategy to design heterodimer compounds was already implemented in the late 1990s by Imbach and his associates, who synthesized the first bisnucleoside phosphates (Puech et al., 1990) . However, those heterodimers were relatively resistant to enzymatic hydrolysis by phosphodiesterases and thus too stable to release the active compounds. Other compounds combining two different anti-HIV agents were later synthesized (Velazquez et al., 1995 (Velazquez et al., , 1999 Pontikis et al., 2000; Laduree et al., 2003) . The general advantage of the heterodimer strategy over using a combination of two drugs is a slow but constant release of active compounds. We previously showed that such strategy was feasible ex vivo and in vivo by developing a depot form of anti-HIV drugs chemically linked (Vanpouille et al., 2014) . Here, we used a similar strategy to combine anti-TB compounds (dU R ) and an anti-HIV compound (AZT) and found that the anti-TB activity of some heterodimers was higher than that of a simple mixture of the parent compounds.
Specifically, we synthesized five dual-targeted HIV/TB heterodimer compounds. Four of them (1e3, 5) inhibit both HIV and TB because these molecules are dimers of the anti-HIV agent AZT and, as the anti-TB agent, either 2 0 -deoxyuridine analogue (1e3) or 5 0 -norcarbocyclic uracil derivative (5). Compound (4) is a heterodimer of two anti-HIV reverse transcriptase inhibitors of different types and was not tested for anti-TB activity. We chose AZT on the basis of Fig. 2 . Cell toxicity of heterodimer-inoculated ex vivo-cultured human lymphoid tissues. Tissue blocks (27 from each individual human tonsil donor) were treated with heterodimers 1e5 corresponding respectively to (AeE) at 10 and 50 mM. At day 12, cells were stained with antieCD3-QD655, antieCD4-QD605, antieCD8-QD800, antieCD45RA-FITC, and antieCCR7-PE-Cy7 (stain 1) or stained with antieCD3-QD655, antieCD4-QD605, antieCD8-QD800, CD25-APC, CD38-PE, CD95-PE-Cy7, and HLA-DR-BV570 (stain 2). We evaluated the cytopathicity of the heterodimers for different cell subsets by comparing the numbers of cells in treated tissue blocks with those in matched untreated control tissue blocks. To account for size differences in tissue blocks, we normalized the data by the weight of the tissues. Presented are means ± SEM (error bars) of six independent experiments performed with tissues from six different donors. CC 50 (concentrations that reduce the viability of the MT-4 by 50%) and IC 50 (concentrations that inhibit MT-4 or CEM cell growth by 50%) with 95% confidence interval (CI)) were calculated by fitting the data points to a sigmoidal doseeresponse curve, using Prism software, (version 6.0; GraphPad). and cultured for 3 days. Cell death (expressed as percent of control) was estimated from three independent experiments, each of them testing five different concentrations (ranging from 10 nM to 300 mM).
our successful experience in developing AZT pro-drugs and the observation that due to its slow release, the PK of the heterodimerized AZT was improved while its toxicity significantly decreased (Vanpouille et al., 2014) . Using Mycobacteria growth indicator tubes, we showed that the newly-synthesized compounds expressed anti-TB activity (compounds 1e3, 5).
The anti-HIV activity was assessed in two different models: MT-4 cell cultures and human tissues ex vivo. MT-4 cell cultures were used because of their typical high level of HIV replication. Human tissue blocks ex vivo (histocultures) were used because they uniquely reflect many important functional aspects of cellecell interactions in vivo. The system of human lymphoid tissue ex vivo was used earlier for preclinical evaluation of microbicides (Grivel & Margolis, 2009; Andrei et al., 2011) .
Using these two systems, we showed that all the tested compounds inhibited HIV replication. In particular, we found that compounds 1e3 were generally more potent that compounds 4e5. The fact that AZT was the anti-HIV agent in all five heterodimers suggests that the breakage of the heterodimers into active molecules was dependent on the nature of the linker as well as on the position of the connection between two components of the hybrid. Thus, the activity of the heterodimers seemed to be directly determined by the hydrolytic stability in this system. Heterodimer 3 was the compound with the most potent anti-HIV activity altogether, because of the two AZT molecules included. Compounds 4 and 5 were less active than 1e3 in the MT-4 cell system, but in the tissue system the difference between activity levels was not so dramatic. It can be assumed that there are additional mechanisms for the hydrolysis of heterodimers 4e5 in lymphoid tissue.
Drug resistance is a major issue in the treatment of TB. Multidrug-resistant TB (MDR TB) is resistant to at least two of the best anti-TB drugs, isoniazid and rifampicin. Commonly, HIV patients with drug-resistant TB have a reduced survival rate compared with those with drug-susceptible TB (Chan and Iseman, 2008; Gunther et al., 2015) . Therefore, it is of critical importance that our dual-targeted compounds active against HIV were active not only against a sensitive TB strain but also against a clinical MDR strain, TB MS-115, that is resistant to the five first-line anti-TB drugs isoniazid, rifampicin, streptomycin, ethambutol, and pyrazinamide.
We compared the activities of the heterodimers with those of the parental drugs. AZT was slightly more active than our newly synthesized compounds. This was not surprising, as AZT alone and dimers would have similar EC 50 only if the dimers were hydrolyzed almost instantaneously and released the AZT moiety. In contrast, dimers are slowly hydrolyzed, allowing constant release of anti-HIV drugs. This is one of the advantages of the heterodimers in addition to targeting two pathogens which potentiate each other. The situation with anti-TB activity was different. Heterodimer 3 showed similar activity to that of its parental dU R against the laboratory strain H37Rv, and was twice as active against the clinical MDRresistant strain MS-115. Such a difference may be explained by the difference in the lengths of the experiments in which the anti-HIV and anti-TB activities were determined: 45 days for evaluation of the anti-TB activity vs. 3 days for MT-4 cell cultures or 12 days for lymphoid tissues to evaluate anti-HIV activity. It is possible that the rate of dimer hydrolysis in anti-TB experiments was not as limiting as in the experiments addressing the anti-HIV activity of the compounds. Since the concentration of the compounds released in the course of the heterodimer hydrolysis are lower than those of the parental compounds added separately, future pharmacokinetics experiments should determine whether there is a risk of generating drug resistance. The concurrent treatment of TB and HIV is generally associated with a higher risk of adverse reactions than the treatment of either infections alone, because of overlapping drug toxicities and drugedrug interactions between antiretroviral therapy and anti-TB therapy (Piggott and Karakousis, 2011; Sterling et al., 2010) . Therefore, an efficient dual-targeted drug has obvious advantages. Nevertheless, we carefully addressed the potential toxicity of our dual-targeted compounds. We addressed this issue in human tissues ex vivo first, as this model does not require exogenous activation, retains the natural cytoarchitecture of tissue, and contains all cell types found in tissue in vivo, thus making this model an adequate tool to approximate cell toxicity in vivo (Biancotto et al., 2009) . To exclude potential depletion of even a small but important subset of cells, we addressed cytotoxity in 12 different cell subsets, and in none of them we did find cell loss at concentrations of compounds that suppressed both HIV and TB. Even when the compounds were used at 50 mM (i.e., between 10 and 350 times the EC 50 depending on the compound), mild cell loss was only noticed for some heterodimers and for some selected subsets. In MT-4 cell cultures, moderate cytotoxicity and cytostaticity were observed for compounds 1, 2, 4, and 5. However, the most active compound (3) was not toxic and was of low cytostaticity (around 4 times lower than AZT itself).
In conclusion, we successfully designed and synthesized five dual-targeted compounds that inhibit HIV and TB in vitro and ex vivo. The compounds described here are the first examples of nucleoside derivatives possessing both anti-HIV and anti-TB activities. Heterodimers 1e5 are depot drugs comprising two active components and having different rates of release: they are either rapidly (1e3) or slowly (4e5) hydrolyzable compounds. To optimize the combination of the active components and their binding linker, further research is needed, in particular evaluation of the pharmacokinetic parameters of anti-HIV and anti-TB agents released in the blood of laboratory animals. We found that one particular heterodimer, compound 3, was the most potent in inhibiting HIV and the drug-resistant TB strain MS-115, being more active than both the parental dU R and the mixture of AZT and dU R (2:1 mol eqv.). This compound 3 was also not toxic and had no cytopathic effect on cell cultures. This is a candidate for future development and further in vivo testing.
